These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 1555478

  • 21. Effect of activated protein C on plasma plasminogen activator inhibitor activity in patients with acute myocardial infarction treated with alteplase: comparison with unfractionated heparin.
    Sakamoto T, Ogawa H, Takazoe K, Yoshimura M, Shimomura H, Moriyama Y, Arai H, Okajima K.
    J Am Coll Cardiol; 2003 Oct 15; 42(8):1389-94. PubMed ID: 14563580
    [Abstract] [Full Text] [Related]

  • 22. Activation of prothrombin accompanying thrombolysis with recombinant tissue-type plasminogen activator.
    Eisenberg PR, Sobel BE, Jaffe AS.
    J Am Coll Cardiol; 1992 Apr 15; 19(5):1065-9. PubMed ID: 1552097
    [Abstract] [Full Text] [Related]

  • 23. Adjunctive use of direct thrombin inhibitors in patients receiving fibrinolytic therapy for acute myocardial infarction.
    French JK, Edmond JJ, Gao W, White HD, Eikelboom JW.
    Am J Cardiovasc Drugs; 2004 Apr 15; 4(2):107-15. PubMed ID: 15049722
    [Abstract] [Full Text] [Related]

  • 24. Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery.
    Leadley RJ, Kasiewski CJ, Bostwick JS, Bentley R, McVey MJ, White FJ, Perrone MH, Dunwiddie CT.
    Thromb Haemost; 1997 Oct 15; 78(4):1278-85. PubMed ID: 9364998
    [Abstract] [Full Text] [Related]

  • 25. Coronary thrombolysis: nonmortality measures of efficacy.
    Belenkie I.
    Can J Cardiol; 1993 Oct 15; 9(6):499-504. PubMed ID: 8221343
    [Abstract] [Full Text] [Related]

  • 26. Lack of interference by heparin with thrombolysis or binding of tissue-type plasminogen activator to thrombi.
    Fry ET, Sobel BE.
    Blood; 1988 May 15; 71(5):1347-52. PubMed ID: 3129047
    [Abstract] [Full Text] [Related]

  • 27. Medical therapy of acute myocardial infarction: Part I. Role of thrombolytic and antithrombotic therapy.
    Jafri SM, Walters BL, Borzak S.
    J Intensive Care Med; 1995 May 15; 10(2):54-63. PubMed ID: 10172420
    [Abstract] [Full Text] [Related]

  • 28. An overview of therapeutic interventions in myocardial infarction. Emphasis on secondary prevention.
    Hinstridge V, Speight TM.
    Drugs; 1991 May 15; 42 Suppl 2():8-20. PubMed ID: 1718703
    [Abstract] [Full Text] [Related]

  • 29. Coronary thrombolysis: adjuvant medical therapy.
    Theroux P, Roy L.
    Can J Cardiol; 1993 May 15; 9(6):524-8. PubMed ID: 8221351
    [No Abstract] [Full Text] [Related]

  • 30. Reperfusion therapy in acute myocardial infarction: present status and controversy.
    Mueller HS.
    Clin Cardiol; 1990 Apr 15; 13(4):239-46. PubMed ID: 2190722
    [Abstract] [Full Text] [Related]

  • 31. Thrombolysis in acute myocardial infarction: analysis of studies comparing accelerated t-PA and streptokinase.
    Smith BJ.
    J Accid Emerg Med; 1999 Nov 15; 16(6):407-11. PubMed ID: 10572811
    [Abstract] [Full Text] [Related]

  • 32. [Low molecular weight heparin (Fraxiparine) as adjunctive therapy with thrombolysis for acute myocardial infarction: a pilot study with a one year follow up].
    Elikowski W, Psuja P, Lewandowski K, Przybył M, Wendland M, Wróblewski D, Jazienicki B, Przybył L, Zawilska K.
    Pol Arch Med Wewn; 1996 Jan 15; 95(1):53-61. PubMed ID: 8677195
    [Abstract] [Full Text] [Related]

  • 33. [t-PA in thrombolytic therapy of acute myocardial infarct].
    Rutsch W, Schmutzler H.
    Herz; 1994 Dec 15; 19(6):336-52. PubMed ID: 7843690
    [Abstract] [Full Text] [Related]

  • 34. Clinical profile of saruplase: angiographic findings.
    Meyer J.
    Int J Clin Pract Suppl; 1998 Nov 15; 99():9-15. PubMed ID: 10344035
    [Abstract] [Full Text] [Related]

  • 35. Analysis of coagulation and fibrinolysis after intravenous anisoylated plasminogen streptokinase activator complex or heparin in patients with acute myocardial infarction. A Belgian multicentre study.
    Renkin J, Beys CC, Lavenne-Pardonge E, Pintens H, Col J.
    Drugs; 1987 Nov 15; 33 Suppl 3():253-60. PubMed ID: 3315603
    [Abstract] [Full Text] [Related]

  • 36. Conjunctive administration of intravenous heparin attenuates cross-linked fibrin degradation in patients treated with streptokinase.
    Galvani M, Abendschein DR, Ferrini D, Ottani F, Rusticali F, Eisenberg PR.
    Thromb Haemost; 1996 Sep 15; 76(3):339-43. PubMed ID: 8883267
    [Abstract] [Full Text] [Related]

  • 37. [Platelet activation in the early phases of acute myocardial infarction].
    Salvioni A, Giraldi F, Assanelli E, Lauri G, Grazi M, Pardea S, Marenzi G.
    Cardiologia; 1998 Aug 15; 43(8):825-32. PubMed ID: 9808873
    [Abstract] [Full Text] [Related]

  • 38. Is survival in acute myocardial infarction related to thrombolytic efficacy or the open-artery hypothesis? A controversy to be investigated with GUSTO.
    Bates ER.
    Chest; 1992 Apr 15; 101(4 Suppl):140S-150S. PubMed ID: 1555479
    [Abstract] [Full Text] [Related]

  • 39. Platelet function and fibrinolytic agents: two sides of a coin?
    Callahan KP, Malinin AI, Gurbel PA, Alexander JH, Granger CB, Serebruany VL.
    Cardiology; 2001 Apr 15; 95(2):55-60. PubMed ID: 11423707
    [Abstract] [Full Text] [Related]

  • 40. [New thrombolytic agents in myocardial infarction].
    Charbonnier B, Lang M, Brochier M.
    Arch Mal Coeur Vaiss; 1987 Nov 15; 80(12):1785-91. PubMed ID: 3128222
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.